Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Open-label, Multicentre, Exploratory Trial of Neoadjuvant Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Next Previous
Search
Trial Profile

Phase II Open-label, Multicentre, Exploratory Trial of Neoadjuvant Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalpiciclib (Primary) ; Exemestane (Primary) ; Pyrotinib (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer; Early breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 16 Feb 2023 Planned number of patients changed from 40 to 30.
  • 16 Feb 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
  • 16 Feb 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top